lowing initial surgery and chemotherapy are rarely cured of their disease by subsequent treatment. 8 Analyses of the utility of dose-escalation of chemotherapeutic agents withThe purpose of this study was to develop a high-dose chemotherapy (HDC) and peripheral blood stem cell out hematopoietic stem cell support in patients with advanced ovarian cancer have produced conflicting (PBSC) regimen for treatment of patients with ovarian carcinoma that could be administered in an outpatient results.
Summary:
lowing initial surgery and chemotherapy are rarely cured of their disease by subsequent treatment. 8 Analyses of the utility of dose-escalation of chemotherapeutic agents withThe purpose of this study was to develop a high-dose chemotherapy (HDC) and peripheral blood stem cell out hematopoietic stem cell support in patients with advanced ovarian cancer have produced conflicting (PBSC) regimen for treatment of patients with ovarian carcinoma that could be administered in an outpatient results. 4, [9] [10] [11] [12] High-dose chemotherapy (HDC) followed by the setting. Fourteen patients with advanced ovarian (n = 9) or breast (n = 5) carcinoma, who had failed conveninfusion of autologous hematopoietic stem cells consistently produces high response rates in patients with tional chemotherapy, were entered into a dose-escalation trial to determine the maximum tolerated dose advanced ovarian carcinoma who have failed chemotherapy; however, these responses are usually of short dur-(MTD) of carboplatin that could be administered with fixed doses of melphalan (160 mg/m 2 ) and mitoxantrone ation with long-term survival in 10-25% of patients.
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High-dose melphalan followed by bone marrow infusion (50 mg/m 2 ). Twenty-five additional patients were included in a phase II trial at the MTD. Two of two was evaluated in 14 patients with stage III-IV ovarian carcinoma who were positive microscopically or macropatients had grade 4 severe regimen-related toxicities (RRT), one fatal, at a dose level of 1600 mg/m 2 . Two of scopically at second-look laparotomy. 22 Five of these 14 patients (37%) were alive and disease-free 30-60 months 29 patients (6.9%) treated at the MTD (carboplatin, 1400 mg/m 2 ) died of RRT. All three patients who died after treatment, suggesting benefit from early intervention with HDC.
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of toxicity had a calculated AUC for carboplatin Ͼ30 mg/ml/min. Thirty-one patients with ovarian cancer More recently, HDC has been utilized as consolidation for patients with advanced ovarian carcinoma who who had failed chemotherapy were treated, 24 at the MTD. Fourteen of 20 patients (70%) with ovarian carciresponded to initial therapy. 23, 24 However, the impact of HDC as consolidation therapy will only be known when noma with evaluable disease achieved a CR and seven (35%) are alive disease-free a median of 20 months appropriate randomized trials are performed. Although several HDC regimens requiring hematopoietic (range, 7-26). Five of seven patients with ovarian cancer who had failed chemotherapy but were rendered clinistem cell support have been evaluated in patients with advanced ovarian carcinoma, no regimen has emerged cally disease-free following surgery survive without progression a median of 13 months (range, 9-19). Eight of which is clearly superior. Melphalan is an ideal agent to incorporate into a high-16 (50%) platinum-resistant and 4/12 (33%) platinumsensitive patients with ovarian cancer survive diseasedose treatment regimen for patients with ovarian carcinoma because of ease of administration, demonstrated activity free. Keywords: high-dose melphalan; mitoxantrone; carbowhen administered at conventional and high doses and the lack of bladder and cardiac toxicity. High-dose melphalan, platin given in single doses has resulted in high response rates in patients with advanced ovarian carcinoma. [16] [17] [18] 22 Furthermore, utilization of melphalan rather than cyclophosphamSurgery and platinum-based chemotherapy produce longide in the HDC regimen allows for more optimal use of term progression-free survival (PFS) in 10-30% of patients cyclophosphamide in induction and/or mobilization with stage III-IV epithelial ovarian carcinoma. [1] [2] [3] [4] [5] Newer regimens. therapeutic agents, such as paclitaxel may improve longHigh doses of carboplatin without hematopoietic stem term survival of patients with ovarian carcinoma. 6, 7 Patients cell support produce responses in patients with advanced who do not achieve a complete pathological response folovarian carcinoma who have failed conventional doses of cisplatin. 25 Carboplatin can be dose-escalated as a single agent to 2000 mg/m 2 when followed by autologous bone
Mitoxantrone has minimal to moderate activity when 2.5 ϫ 10 6 CD34 + cells/kg. 36 Peripheral blood stem cells were infused 48 h after carboplatin administration (day 0). used at conventional doses for the treatment of ovarian carcinoma. [27] [28] [29] However, in vitro assays of drug sensitivity demonstrate a steep dose-response curve for mitoxantrone Administration of melphalan, mitoxantrone, carboplatin and at high concentrations it is one of the most active (MMC) agents for the killing of ovarian carcinoma cells. 30 Mitoxantrone has also been used successfully for intraperitoneal Melphalan 160 mg/m 2 was administered intravenously over therapy where high concentrations of drug can be 30-60 min on day −4, mitoxantrone 25 mg/m 2 was adminachieved. 31, 32 istered over 50 min on days −4 and −3 and carboplatin In vitro studies have shown that mitoxantrone, when 1000 mg/m 2 -1600 mg/m 2 was administered intravenously added to high concentrations of melphalan, produces over 45-60 min on day −3 ( Table 2 ). Treatment with MMC greater than additive cytotoxicity against platinum-sensitive was begun a median of 39 days (range, 26-111) following and platinum-resistant breast cancer cell lines. 33 Mitoxanthe administration of mobilization chemotherapy. trone (60 mg/m 2 ) has been combined with high-dose melphalan (180 mg/m 2 ) followed by autologous bone marrow infusion in patients with refractory malignancies
Regimen-related toxicity grading with less toxicity than was observed when combined with Regimen-related toxicities (RRT) were graded prospeccyclophosphamide. 14, 34 tively from day −5 to day 28 post-PBSC infusion using the For the above reasons, a high-dose regimen of melcommon toxicity criteria. 37 Regimen-related toxicity was phalan, mitoxantrone and carboplatin (MMC) followed by defined as grade 4 toxicity that did not resolve within 30 peripheral blood stem cell (PBSC) infusion was evaluated.
days. The maximum tolerated dose (MTD) of carboplatin that could be administered with fixed doses of melphalan and mitoxantrone was determined in patients with ovarian or Phase I patient allocation breast cancer and a limited phase II study was carried out predominantly in patients with ovarian carcinoma.
The method of patient allocation was designed to avoid dose levels associated with Ͼ20% probability of unresolved grade 4 non-hematologic RRT. The starting dose of Materials and methods carboplatin was 1000 mg/m 2 (dose level 1) and the dose was escalated in 200 mg/m 2 increments to 1600 mg/m 2 (dose level 4) in groups of four patients each (Table 2) .
Patient selection
Patients were treated at the next higher dose level if no Between August 1994 and July 1995, 39 patients were unresolved grade 4 RRT occurred in four consecutive enrolled on a HDC study: 14 on a phase I dose-escalation patients. If 1/4 patients developed unresolved grade 4 RRT trial to determine the MTD of carboplatin that could be an additional four patients were accrued at this dose level. administered with fixed doses of mitoxantrone and melIf 2/4 patients developed unresolved grade 4 RRT, the next phalan and 25 on a phase II study with treatment at the cohort received a lower dose level. Additional patients were MTD (Table 1 ).
accrued at the dose level that would indicate a Ͼ80% probPatients were eligible for the study if they had stage 4 ability that the incidence of unresolved grade 4 RRT would breast cancer, relapsed ovarian carcinoma or stage 3-4 not exceed 20%. ovarian carcinoma who failed to achieve a CR to initial chemotherapy. Additional inclusion criteria included: age of 70 years or less, ECOG performance status of 0-2 and evidence of adequate hepatic, renal and cardiac function. Table 1 Phase I dose escalation trial
Patients were treated on an FDA-registered protocol approved by the institutional review board of the hospital
Patient characteristics n = 14 (%)
where the therapy was administered and all gave informed consent. tim 6 g/kg/day or filgrastim alone without chemotherapy (n = 1). 35, 36 The techniques of apheresis, cryopreservation,
Median age, years 52 (range) thawing and infusion have been described elsewhere.
35
Apheresis was performed daily with the goal of collecting 125 levels had to have normal levels for a minimum of 4 weeks. A partial remission (PR) was defined as a greater than 50% reduction of the sum of the products of the perResults pendicular diameters of all measurable disease, and a 50% decrease of the CA-125 level for a minimum of 4 weeks.
Phase I trial Definitions Patient characteristics: Characteristics of the 14 patients (nine with ovarian and five with breast carcinoma) enrolled Neutrophil engraftment was defined as the first of 3 conin the phase I trial are shown in Table 1 . secutive days on which the absolute neutrophil count (ANC) exceeded 0.5 ϫ 10 9 /l following the nadir. Platelet Protocol compliance: All 14 patients received the pretransfusion independence was defined as the first of 7 conscribed doses of drugs and were evaluable for toxicity. secutive days on which the platelet count exceeded 20 ϫ 10 9 /l unsupported by transfusions. Toxicities (Table 2 ): None of the 12 patients enrolled at Interstitial pneumonia syndrome (IPS) was defined as dose levels 1, 2 or 3 developed grade 4 unresolved RRT. diffuse pulmonary infiltrates without identifiable infecBoth patients enrolled at dose level 4 experienced grade tious cause. 38 4 unresolved RRT; one developed gross hematemesis and Patients with ovarian cancer progressing while receiving endoscopy showed esophageal necrosis which led to esoor relapsing within 6 months of completing platinum-based phageal stenosis; this patient is alive without relapse at day therapy were classified as platinum-resistant. Patients fail-548. One patient died of IPS on day 9. ing platinum-based therapy greater than 6 months from Dose level 3 was deemed to be the MTD. completion were classified as platinum-sensitive. Table 3 . Twenty-nine patients (including the four entered treatment facility with daily surveillance for complications on dose level 3 of the phase I trial) were treated at the warranting hospital admission such as febrile neutropenia putative MTD of dose level 3. or inadequate oral intake. 35 All patients received filgrastim 6 g/kg/day from the day of PBSC infusion until the ANC Protocol compliance: All 29 patients received the prewas Ͼ0.5 ϫ 10 9 /l for 3 consecutive days. scribed doses of drugs followed by infusion of PBSC.
Statistics
Non-hematologic toxicities: Non-hematologic toxicities encountered in these 29 patients are shown in Table 4 . Two All data were collected using a custom-designed distributed data system, reviewed at a central clinical trials center of 29 (6.9%) patients enrolled at dose level 3 died from RRT; one from an intracerebral hemorrhage on day 5 and (Response Oncology, Inc., Memphis, TN, USA) and analyzed using the SAS system (SAS Institute, Cary, NC, one from renal failure on day 4. The most frequent severe complication was grade 4 mucositis which occurred in 34% USA). Actuarial probabilities were calculated using the method of Kaplan and Meier. 40 The endpoints for survival of patients. were compared to mg/m 2 dosing as shown in Figure 1 . Table 4 Grade 3-4 toxicity observed at the MTD (n = 29)
Three of four patients with unresolved grade 4 non-hematologic toxicities, and all three toxic deaths, had calculated
Grade AUC values Ͼ30 mg/ml/min while 1/35 had unresolved grade 4 non-hematologic toxicities with calculated AUC
(%) 4 (%)
values Ͻ30 mg/ml/min (P = 0.0005). The median AUC for the four patients who developed grade 4 unresolved non- Twenty-eight of 29 patients were hospitalized for a median of 14 (range 5-42) days.
Toxicity and calculated AUC for carboplatin (phase I and II trials)
Data sufficient to calculate expected AUC for carboplatin were available on 38 patients. The median calculated AUC values (mg/ml/min) were: 17.2 (range, 16.3-23.7) for three of the four patients in dose level 1, 18.2 (range, 14.6-19.9) for the four patients in dose level 2, 22.2 (range, 12.7-39.9) recovery. The median days to achieve an ANC of Discussion 0.5 ϫ 10 9 /l and platelets of 20 ϫ 10 9 /l were 10 (range, 3-15) and 11 (range, 0-20), respectively.
The phase I part of this study determined that 1600 mg/m 2 of carboplatin, given with 160 mg/m 2 of melphalan and 50 mg/m 2 of mitoxantrone resulted in excessive toxicity. At this dose level, one patient developed life-threatening gasResponse and outcome trointestinal toxicity and one died of IPS. At the 1400 mg/m 2 level there were 2/29 treatment-related deaths Breast carcinoma: Two of six patients with measurable (6.9%); one from renal failure and one from a CNS disease had a CR, two a PR and two NR. Three of eight hemorrhage. Thirty-four per cent of patients had severe patients survive 16-26+ months after PBSC infusion; none mucositis. Significant creatinine elevations occurred in two are disease-free.
patients and renal failure occurred in one patient, who was heavily pre-treated with cisplatin. In a previously reported phase II trial of mitoxantrone Ovarian carcinoma (Table 5 and Figure 2 ): Three of 31 (10%) patients (one, NED; one second CR; one, relapse) (75 mg/m 2 ), carboplatin (1500 mg/m 2 ) and cyclophosphamide (120 mg/kg) followed by bone marrow transplantation died early of RRT and were not evaluable for response; one was treated at dose level 4 in the phase I and two at there was 1/30 (3%) treatment-related death due to aspergillus. 21 In that study diarrhea and mucositis were frequent dose level 3 in the phase II trial.
Seventeen of 31 (55%) are alive a median of 16 months and severe but there were no regimen-related deaths and no patient developed renal failure. 21 However, all patients (range, 7-27), 13 (42%) are alive without progression a median of 15 months (range, 7-26) and 12 (39%) are alive in that study received mannitol and carboplatin by continuous infusion, which could have decreased the severity of disease-free a median of 16 months (range, 7-26). The probabilities of survival and EFS at 18 months were 0.60 renal complications. The current study was designed to administer carboplatin and 0.30, respectively (Figure 2 ). The probability of relapse or progression was 0.66.
on a mg/m 2 basis. Calvert et al 41 have documented the importance of dosing by a calculated target AUC formula Five of the seven patients who were NED after surgery are alive without progression a median of 13 months which compensates for renal function, age and gender when conventional doses of carboplatin are administered. How-(range, 9-19). The patient treated in third CR progressed 16 months after treatment and is still alive at 23 months.
ever, Shea et al 26 Eight of 12 platinum-resistant patients achieved a CR in the current study demonstrated overlap of estimated AUC values for carboplatin at all four dose levels with a and five remain in remission.
None of three patients treated at dose level 1 (carboplatin range of 12.7-39 mg/ml/min at the MTD of 1400 mg/m 2 . All three fatal toxicities occurred in patients with an esti-1000 mg/m 2 ), 1/2 at dose level 2 (carboplatin 1200 mg/m 2 ), 10/24 at dose level 3 (carboplatin 1400 mg/m 2 ) and 1/2 at mated AUC Ͼ30 mg/ml/min suggesting that toxicity was more closely related to estimated AUC than to dose/m 2 . dose level 4 (1600 mg/m 2 ) are surviving disease-free. Eight of 20 (40%) patients who received cyclophosphamThese data suggest that the MTD for a targeted AUC would be in the 20-25 mg/ml/min range. Whether or not dosing ide and paclitaxel and 4/11 (36%) patients receiving CE or CEP prior to collection of PBSC are alive and diseaseby targeting a specific AUC would reduce actual variability in carboplatin blood levels can only be determined by direct free, respectively. or a higher probability of relapse. 
